Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140903 | 1.00 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL31066913 | 1.00 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL7502732 | 0.90 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL7501078 | 0.86 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL7493988 | 0.85 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL7497088 | 0.84 | PDE5A (0.72) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL7504986 | 0.84 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL7499068 | 0.84 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL31034788 | 0.83 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL2458882 | 0.83 | PDE5A (1.00) | PDE5ACLK4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | claimed |
| EP-4692320-A1 | STRUCTURE AND EVALUATION METHOD USING STRUCTURE | The University of Tokyo (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260002132-A1 | METHOD FOR PRODUCING RENAL COLLECTING DUCT CELLS AND PELVIC EPITHELIAL CELLS | UNIV KYOTO (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250163385-A1 | METHOD FOR PRODUCING LUNG MESENCHYMAL CELLS AND LUNG MESENCHYMAL CELLS | KYOTO UNIVERSITY (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4530344-A1 | PRODUCTION METHOD FOR RENAL COLLECTING DUCT CELLS AND PELVIC EPITHELIAL CELLS | Kyoto University (JP) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024219499-A1 | STRUCTURE AND EVALUATION METHOD USING STRUCTURE | 国立大学法人 東京大学 | 2024-10-24 | — | — | WO | disclosed |
| EP-4372075-A1 | STRUCTURE AND USE THEREOF | Cellfiber Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023228908-A1 | PRODUCTION METHOD FOR RENAL COLLECTING DUCT CELLS AND PELVIC EPITHELIAL CELLS | 国立大学法人京都大学 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023149407-A1 | LUNG MESENCHYMAL CELLS AND METHOD FOR PRODUCING LUNG MESENCHYMAL CELLS | 国立大学法人京都大学 | 2023-08-10 | — | — | WO | disclosed |
| WO-2023286852-A1 | STRUCTURE AND USE THEREOF | 株式会社セルファイバ | 2023-01-19 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20050112717-A1 | Detection of NO by using guanylyl cyclase and cGMP production as a readout system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
| EP-0607439-B1 | NITROGENOUS HETEROCYCLIC COMPOUND | EISAI CO LTD (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6046206-A | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| CN-1071164-A | Nitrogen-containing heterocycle compound | EISAI CO LTD (JP) | 1993-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002132-A1 | METHOD FOR PRODUCING RENAL COLLECTING DUCT CELLS AND PELVIC EPITHELIAL CELLS | AQP1, AQP3, ALPG | PDE5A 14/4885CLK4 1591/4885MEN1 4500/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | PDE5A 349/4885CLK4 3315/4885MEN1 4080/4885 |
| US-20050112717-A1 | Detection of NO by using guanylyl cyclase and cGMP production as a readout system | PDE2A, PDE5A, GUCY1A2 | PDE5A 2/4885CLK4 3373/4885MEN1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.